KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201.

Charalambos Andreadis, Olivia Bobek, Eric D Hsi, Timothy S Fenske, Patrick J Stiff, Brian T Hill, Susan M Geyer, Mitchell Horwitz, Farhad Khimani, Richard F Little, Shira N Dinner, Jonathan W Friedberg, Brad S Kahl, Miguel-Angel Perales, Steven M Devine, John P Leonard, Nancy L Bartlett

Leuk Lymphoma 66(10) 1903-1912

PMID40632607
PMCIDPMC12321088
DOI10.1080/10428194.2025.2525982
发表日期2025-07-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1::CONSORT/入组流程图;Figure 2::非 KM 图;Figure 3::非 KM 图。
摘要

摘要

To improve outcomes in relapsed or refractory activated B-cell type Diffuse Large B-cell Lymphoma (ABC-DLBCL), we launched a randomized phase 3 trial evaluating 2-year progression free survival (2yPFS) with the addition of ibrutinib to autologous transplant. Patients received ibrutinib 560 mg or placebo with conditioning and for 12 additional cycles. Accrual was adversely affected by implementation of the ABC classifier in this setting and the changing treatment landscape of DLBCL. In all, 39 patients on ibrutinib and 38 on placebo were evaluable. 2yPFS was 57.6% on ibrutinib versus 40.8% on placebo (p = 0.09). We observed a higher incidence of grade ≥3 sepsis (10% vs 5%) and mucositis (13% vs. 3%) on ibrutinib but similar rates of atrial fibrillation. There were 4 fatalad verse events in the ibrutinib arm due to infection. Ibrutinib added to transplant may improve 2yPFS in relapsed/refractory ABC-DLBCL but future clinical trials should incorporate more efficient patient selection.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1:CONSORT diagram and patient disposition. AE: adverse event
非 KM Figure
Figure 2:Progression-free survival. (A) progression-free survival for the study cohort by modified intent to treat analysis. There were 15 PFS events on the ibrutinib arm: 9 progressions (6 followed by death) and 6 deaths without lymphoma progression. There were 21 PFS events on the placebo arm: 20 progressions (11 followed by death) and 1 death without progression. 2-year PFS in the modified ITT population was 57.6% (95% CI, 42.1% to 78.8%) in the ibrutinib arm vs. 40.8% (95% CI, 26.5 to 62.8%) in the placebo arm. Median PFS was 26.5 months (95% CI, 10.2 to not reached [NR]) vs. 8.1 months (95% CI, 5.4 to NR), respectively. The estimated stratified HR for PFS was 0.54 (95% CI, 0.26 to 1.10; log-rank p=0.09). ( B) progression-free survival for the patients with treatment-refractory disease or early progression by modified intent to treat analysis. Median PFS was NR (95% CI, 6.7 months to NR) on ibrutinib vs. 6 months (95% CI, 3.7 to NR) on placebo. The estimated HR for PFS was 0.39 (95% CI, 0.13-1.16; log-rank p=0.08).
非 KM Figure
Figure 3:Overall survivalby modified intent to treat analysis. The estimated HR for OS was 0.87 (95% CI, 0.38 to 2.01) and the estimated 2-year survival was 69.5% (95 CI, 55.3 to 87.4%) in the ibrutinib arm vs. 68.3% (95% CI, 54.3 to 86.0%) in the placebo arm (stratified log-rank P=0.7)
非 KM Figure